American Portfolios Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

American Portfolios Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$50.8K	Hold	44,939	–	–	﹤0.01%	1693
2022 Q2	$71K	Hold	44,939	–	–	﹤0.01%	1579
2022 Q1	$69.2K	Sell	44,939 -8,345	-16%	-$12.9K	﹤0.01%	1726
2021 Q4	$131K	Sell	53,284 -20	-0%	-$47	﹤0.01%	1381
2021 Q3	$134K	Hold	53,304	–	–	0.01%	1317
2021 Q2	$152K	Hold	53,304	–	–	0.01%	1237
2021 Q1	$125K	Buy	53,304 +41,600	+355%	+$99.9K	0.01%	1235
2020 Q4	$20.6K	Sell	11,704 -1,814	-13%	-$2.54K	﹤0.01%	1804
2020 Q3	$12.7K	Buy	13,518 +13,504	+96,457%	+$11.9K	﹤0.01%	1885
2020 Q2	$12	Hold	14	–	–	﹤0.01%	2837
2020 Q1	$12	Hold	14	–	–	﹤0.01%	2765
2019 Q4	$12	Hold	14	–	–	﹤0.01%	2839
2019 Q3	$14	Hold	14	–	–	﹤0.01%	2822
2019 Q2	$15	Hold	14	–	–	﹤0.01%	2721
2019 Q1	$18	Buy	+14	New	+$17	﹤0.01%	2604

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

American Portfolios Advisors's LCTX Position: Q3 2022 in Review

American Portfolios Advisors held its Lineage Cell Therapeutics (LCTX) position steady in Q3 2022 at 44,939 shares worth $50.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1693.

American Portfolios Advisors first reported a position in LCTX in Q1 2019 and has held it in 15 quarters since. The position peaked at $152K in Q2 2021. 105 funds tracked by Wall St. Rank hold LCTX as of Q3 2022.

American Portfolios Advisors held 44,939 shares of Lineage Cell Therapeutics worth $50.8K as of Q3 2022.
American Portfolios Advisors left its Lineage Cell Therapeutics share count unchanged in Q3 2022.
Lineage Cell Therapeutics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #1693 holding.
American Portfolios Advisors first reported a position in Lineage Cell Therapeutics in Q1 2019 and has held it in 15 quarters since.
American Portfolios Advisors's Lineage Cell Therapeutics position peaked at $152K in Q2 2021.
105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.